Safe Prescribing for Pain
This activity outlines the prevalence of prescription opioid abuse in the United States and the skills and tools clinicians can use to screen for and prevent abuse in patients with pain.

Safe Prescribing for Pain

Gayathri Dowling, PhD; Richard A. Denisco, MD

This test-and-teach case is an educational activity modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will see whether you answered correctly and can then read evidence-based information that supports the most appropriate answer choice. Please note that these questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the case, there will be a short post-test assessment based on material covered in the activity.

The goal of this activity is to describe the prevalence of prescription opioid abuse in the United States and the skills and tools clinicians can use to screen for and prevent abuse in patients with pain.

Educational Objectives

Upon completion of this activity, participants will be able to:

Communicate effectively with patients regarding opioid use and abuse

Use appropriate opportunities to screen for drug use, including nonmedical use of prescription drugs

Evaluate patient risk for opioid pain medication abuse through screening and monitoring

Recognize the extent and potential for abuse of prescription opioids

Employ prescribing practices that support safe use of prescription opioids

Accreditation Statement

This activity has been reviewed and is approved for AAPA Category 1 CME credit by the Physician Assistant Review Panel. Participants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with the AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.  This CME activity expires October 2, 2015.

 

Disclosure Policy Statement

It is the policy of the American Academy of Physician Assistants to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following: 

Gayathri J. Dowling, PhD
Acting Chief, Science Policy Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

Disclosure: Gayathri J. Dowling, PhD has disclosed no relevant financial relationships.  Dr. Dowling does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States. Dr. Dowling does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Richard A. Denisco, MD
Medical Officer, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

Disclosure: Richard A. Densico, MD, has disclosed no relevant financial relationships. Dr. Denisco does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States. Dr. Denisco does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jane Lowers
Group Scientific Director, Medscape LLC
Disclosure: Jane Lowers has disclosed no relevant financial relationships.

Neil Chesanow
Senior Clinical Editor, Medscape, LLC
Disclosure: Neil Chesanow has disclosed no relevant financial relationships.

Lynne Kolton Schneider, PhD
Freelance Writer, Boca Raton, FL
Disclosure: Lynne Kolton Schneider has disclosed no relevant financial relationships.

Robert Carroll, PhD, RN
Project Director, IQ Solutions, Rockville, MD
Disclosure: Robert Carroll, PhD, RN, has disclosed no relevant financial relationships.

Denise Crute, MA
Director of Training, IQ Solutions, Rockville, MD
Disclosure: Denise Crute, MA has disclosed no relevant financial relationships.

Bill H. McCarberg, MD
Primary Care Physician, Adjunct Assistant Clinical Professor, University of California, San Diego; Founder, Chronic Pain Management Program, Kaiser Permanente, San Diego, CA

Disclosure: Bill McCarberg, MD, has disclosed the following relevant financial relationships.  Served as an advisor or consultant for: PriCara; Forest Laboratories, Inc.; Endo Pharmaceuticals; Sucampo Pharmaceuticals, Inc.; NeurogesX, Inc.; Teva Pharmaceuticals; Insys Therapeutics, Inc; QRX Pharma Ltd; Salix Pharmaceuticals, Inc.

Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC
Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Laurie E. Scudder, DNP, NP
Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC
Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this activity.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Supported by the National Institute on Drug Abuse, a U.S. Dept of Health and Human Services agency, and the Office of National Drug Control Policy


Type:     Internet Activity (Enduring Material)
1804 Registered Users
Credits
1.25 Credits> American Academy of Physician Assistants> AAPA Category 1 CME credit